Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epithelial sodium channel subunit beta (SCNN1B), also known as amiloride-sensitive sodium channel subunit beta, is a key component of the heterotrimeric epithelial sodium channel (ENaC). ENaC is a non-voltage-gated, amiloride-sensitive channel primarily expressed in the apical membrane of tight epithelia, including the distal nephron of the kidney, respiratory airways, colon, and sweat glands. It plays a critical role in regulating body fluid volume, sodium balance, and systemic blood pressure by mediating the electrogenic reabsorption of sodium ions, with water following osmotically.
Mutations in the SCNN1B gene are associated with severe human disorders. Gain-of-function mutations that disrupt the channel's degradation pathway lead to Liddle syndrome, an autosomal dominant form of severe, early-onset hypertension characterized by hypokalemia and suppressed renin and aldosterone levels. Conversely, loss-of-function mutations cause autosomal recessive pseudohypoaldosteronism type 1 (PHA1B), a life-threatening salt-wasting syndrome characterized by severe hyponatremia, hyperkalemia, and dehydration. SCNN1B is a well-established therapeutic target; classic potassium-sparing diuretics such as amiloride and triamterene act as direct blockers of the ENaC pore, thereby promoting natriuresis while conserving potassium. Additionally, novel therapeutic strategies, such as SCNN1B-targeting siRNAs, are being explored for respiratory conditions like cystic fibrosis and chronic obstructive pulmonary disease to restore airway surface liquid hydration.
Epithelial sodium channel blocker, gene silencing
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epithelial sodium channel subunit beta (SCNN1B).